Cases & Deals

  • Home
  • Practices
  • Celgene defends REMS patents against Kyle Bass' IPR petitions

Share

Celgene defends REMS patents against Kyle Bass' IPR petitions

April 2015

Client(s) Celgene Corporation

Jones Day is representing Celgene Corporation in defending four IPR petitions filed by Coalition for Affordable Drugs VI LLC - a company formed by hedge fund manager Kyle Bass - against U.S. Patent Nos. 6,045,501 and 6,315,720, which are listed in the Orange Book for Celgene's REVLIMID®, POMALYST®, and THALOMID® brand drugs, and which pertain to Celgene's Risk Evaluation and Mitigation Strategy (REMS)™ for those drugs.

Coalition for Affordable Drugs VI LLC et al. v. Celgene Corporation, IPR2015-01102 (PTAB)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.